Results 171 to 180 of about 786,579 (199)

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Blood Cancer Journal
Thomas Roberts, Grace Uwenedi, Rachel Bruton, Graham McIlroy, Sarah Damery, Panagiota Sylla, Nicola Logan, Sam Scott, May Lau, Ahmed Elzaidi, Siobhan Plass, Soumyajit Mallick, Katie Spencer, Christine Stephens, Christopher Bentley, Guy Pratt, Jianmin Zuo, Shankara Paneesha, Brian Willett, Paul Moss, Helen Parry   +20 more
doaj   +1 more source

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy. [PDF]

Cancer Biol Med
Hu S, Wu Z, Dai Y, Shi X, Hu Q, Liu C, Zhu Y, Yu R, Li J, Liu Y, Liu T, Lu L, Yao C, Shen B, Shi M, Chen C, Wang X, Zhou G.   +17 more
europepmc   +1 more source

Pan-cancer analysis identified DOK3 as a novel biomarker for predicting prognosis and immunotherapy effectiveness

Zichen Xu, Lin Cai, Qingkun Jiang, Yuqi Xin, Shaoqing Chen, Jianwei Liu   +5 more
openalex   +1 more source

Merkel cell carcinoma immunotherapy: key questions in the era of immune checkpoint blockade. [PDF]

J Immunother Cancer
Becker JC, Lodde G, Haist M, Ugurel S.
europepmc   +1 more source

Editorial: Crosstalk in tumor microenvironments: shaping early drug and immunotherapy strategies. [PDF]

Front Immunol
Froechlich G, Arcucci A, Sasso E.
europepmc   +1 more source

<i>Post-hoc</i> analysis of real-world retrospective study on neoadjuvant chemotherapy combined with immunotherapy for stage I-III non-small cell lung cancer. [PDF]

Front Immunol
Shao Y, Wang S, Yu Y, Yang W, Song L, Wuyuntanghesi, Zhao Y.   +6 more
europepmc   +1 more source

Targeting Dermatologic Side Effects of Immunotherapy Using Novel Skin Care Products. [PDF]

J Cancer
Claes M, Lodewijckx J, Robijns J, Tuts L, Lenaerts M, Vandaele E, Wessels T, Requilé A, Luyten D, Verheezen Y, Joosens E, Mebis J.   +11 more
europepmc   +1 more source

Case Report: Multimodal immunotherapeutic regimen (envafolimab + chemotherapy + radiotherapy) for four synchronous primary malignant neoplasms: a case report of 33-month survival and implications for tumor immunology. [PDF]

Front Oncol
Liu Y, Zhang Y, Zhang Y, Duan X, Gao Z, Zhang X, Zhao J.   +6 more
europepmc   +1 more source